Some hand OA patients with an inflammatory phenotype have structural benefit from lower dose MTX (but no difference with pain or function, but no difference with adverse events). Why the disconnect? And what’s a rheumatologist to do? Nice, France #ACR19 ABST1759 @RheumNow https://t.co/4SvWzps9DU